Endoplasmic reticulum stress as a novel mechanism in amiodaroneinduced destructive thyroiditis

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 1, 2015, Pages E1-E10

  Lombardi, Angela ^a   Inabnet, William Barlow ^a   Owen, Randall ^a   Farenholtz, Kaitlyn Ellen ^a   Tomer, Yaron ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; AMIODARONE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; INITIATION FACTOR 2ALPHA; IODINE; MESSENGER RNA; PROTEASOME; PROTEIN IRE1; TAUROURSODEOXYCHOLIC ACID; THAPSIGARGIN; THYROGLOBULIN; X BOX BINDING PROTEIN 1; ANTIARRHYTHMIC AGENT; DNA BINDING PROTEIN; HEAT SHOCK PROTEIN; INITIATION FACTOR 2; MOLECULAR CHAPERONE GRP78; REGULATORY FACTOR X TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR;

ADVERSE DRUG REACTION; AMIODARONE INDUCED DESTRUCTIVE THYROIDITIS; ARTICLE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; EXPERIMENTAL DESIGN; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOLECULAR DYNAMICS; PRIMARY THYROCYTE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN HOMEOSTASIS; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; THYROID CELL; UNFOLDED PROTEIN RESPONSE; UPREGULATION; CELL LINE; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; METABOLISM; THYROID GLAND; THYROIDITIS;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; CELL LINE; DNA-BINDING PROTEINS; DOWN-REGULATION; ENDOPLASMIC RETICULUM STRESS; EUKARYOTIC INITIATION FACTOR-2; HEAT-SHOCK PROTEINS; HUMANS; THYROGLOBULIN; THYROID GLAND; THYROIDITIS; TRANSCRIPTION FACTOR CHOP; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84920570441     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2745     Document Type: Article

References (52)

1. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of C ardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011;57:e101-e198.
2. Vassallo P, Trohman RG. Prescribing amiodarone: an evidencebased review of clinical indications. JAMA. 2007;298:1312-1322.
3. Han TS , Williams GR, Vanderpump MP. Benzofuran derivatives and the thyroid. Clin Endocrinol (Oxf). 2009;70:2-13.
4. Ahmed S, Van Gelder IC, Wiesfeld AC, Van Veldhuisen DJ, Links TP. De terminants and outcome of amiodarone-Associated thyroid dysfunction. Clin Endocrinol (Oxf). 2011;75:388-394.
5. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-Analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet. 1997;350:1417-1424.
6. Yamazaki K, Mitsuhashi T, Yamada E, e t al. Amiodarone reversibly decreases sodium-iodide symporter mRNA expression at therapeutic concentrations and induces antioxidant responses at supraphysiological concentrations in cultured human thyroid follicles. Thyroid. 2007;17:1189-1200.
7. Bogazzi F, Bartalena L, Gasperi M, Braverman LE, Martino E. The various effects of amiodarone on thyroid function. Thyroid. 2001; 11:511-519.
8. Bogazz i F, Tomisti L, Bartalena L, Aghini-Lombardi F, Martino E. Amiodarone and the thyroid: a 2012 update. J Endocrinol Invest. 2012;35:340-348.
9. Franklyn JA,Gammage MD. Treatment of amiodarone-Associated thyrotoxicosis Nat Clin Pract Endocrinol Metab. 2007 3 662-666.
10. Osman F, Franklyn JA, Sheppard MC, Gammage MD. Successful treatment of amiodarone-induced thyrotoxicosis. Circulation. 2002;105:1275-1277.
11. Bogazzi F, Bartalena L, Brogioni S, et al. Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis. T hyroid. 1997;7:541-545.
12. Bogazzi F, Bartalena L, Dell'Unto E, et al. Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy. Clin Endocrin ol (Oxf). 2007;67:533-537.
13. Schonberger J, Bauer J, Spruss T, et al. Establishment and characterization of the follicular thyroid carcinoma cell line ML-1. J Mol Med (Berl). 2000;78:102-110.
14. Huber AK, Finkelman FD, Li CW, et al. Genetically driven target tissue overexpression of CD40: a novel mechanism in autoimmune disease. J Immunol. 2012;189:3043-3053.
15. Lombardi A, Ulianich L, Treglia AS, et al. Increased hexosamine biosynthetic pathway flux dedifferentiates INS-1E cells and murine islets by an extracellular signal-regulated kinase (ERK)1/2-mediated signal transmission pathway. Diabetologia. 2012;55:141-153.
16. Kuznetsov G, Bush KT, Zhang PL, Nigam SK. Perturbations in maturation of secretory proteins and their association with endoplasmic reticulum chaperon es in a cell culture model for epithelial ischemia. Proc Natl Acad Sci USA. 1996;93:8584-8589.
17. Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313:1137-1140.
18. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011;334:1081-1086.
19. Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell. 2001; 107:881-891.
20. Kim PS, Bole D, Arvan P. Transient aggregation of nascent thyroglobulin in the endoplasmic reticulum: relationship to the molecular chaperone, BiP. J Cell Biol. 1992;118: 541-549.
21. Medeiros-Neto G, Kim PS, Yoo SE, et al. Congenital hypothyroid goiter with deficient thyroglobulin. Identification of an endoplasmic reticulum storage disease with induction of molecular chaperone s. J Clin Invest. 1996;98:2838-2844.
22. Di Jeso B, Formisano S, Ulianich L. Perturbation of cellular calcium delays the secretion and alters the glycosylation of thyroglobulin in FRTL-5 cells. Biochem Biophys Res Commun. 1997;234:133-136.
23. Yoshida H. ER stress and diseases. FEBS J. 2007;274:630-658.
24. Werner ED, Brodsky JL, McCracken AA. Pro teasome-dependent endoplasmic reticulum-Associated protein degradation: an unconventional route to a familiar fate. Proc Natl Acad Sci USA. 1996; 93:13797-13801.
25. Travers KJ, PatilCK,Wodicka L, Lockhar t DJ, Weissman JS, Walter P. Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-Associated degradation. Cell. 2000;101:249-258.
26. D'Ascia SL, D'Ascia C, Marino V, et al. Cardiac resynchronisation therapy response predicts occurrence of atrial fibrillation in nonischaemic dilated cardiomyopathy. Int J Clin Pract. 2011;65:1149-1155.
27. Cairns JA. Antiarrhythmic therapy in the post-infarction setting: update from major amiodarone studies. Int J Clin Pract. 1998;52: 422-424.
28. Todd DJ, Lee AH, Glimcher LH. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol. 2008; 8:663-674.
29. Nagaraju K, Raben N, Loeffler L, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA. 200 0;97:9209-9214.
30. Mear JP, Schreiber KL, Munz C, et al. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J Immun ol. 1999;163: 6665-6670.
31. Purcell AW,Todd A,Kinoshita G,et al Association of stress proteins with autoantigens: a possible mechanism for triggering autoimmunity? Clin Exp Immunol. 2003;132 193-200.
32. Blass S, Union A, Raymackers J, et al. The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis. Arthritis Rheum. 2001;44:761-771.
33. Bertolotti A, Wang X, Novoa I, et al. Increased sensitivity to dextran sodium sulfate colitis in IRE1-deficient mice. J Clin Invest. 2001; 107:585-593.
34. Seimon TA, Wang Y, Han S, et al. Macrophage deficiency of p38alpha MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice. J Clin Invest. 2009;119:886-898.
35. LinW,Bailey SL,HoH, et al. The integrated stress response prevents demyelination by protecting oligodendrocytes against immune-mediated damage. J Clin Invest. 2007;117:448-456.
36. Yamasaki S, Yagishita N, Tsuchimochi K, Nishioka K, Nakajima T. Rheumatoid arthritis as a hyper-endoplasmic-reticulum-Associated degradation disease. Arthritis Res Ther. 2005;7:181-186.
37. Hetz C, Chevet E, Harding HP. Targeting the unfolded protein response in disease. Nat Rev Drug Discov. 2013;12:703-719.
38. Hebert DN, Molinari M. In and out of the ER: protein folding, quality control, degradation, and related human diseases. Physiol Rev. 2007;87:1377-1408.
39. Kim IY, Kang YJ, Yoon MJ, et al. Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregul ation. Neuro Oncol. 2011;13:267-279.
40. Burrows JA, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant-1-Antitrypsin (-1-AT) Z: a potential pharmacological strateg y for prevention of liver injury and emphysema in-1-AT deficiency. Proc Natl Acad Sci USA. 2000; 97:1796-1801.
41. Ozcan L, Ergin AS, Lu A, et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 2009; 9:35-51.
42. Xiao C, Giacca A, Lewis GF. Sodium phenylbutyrate, a drug with known capacity to reduce endoplasmic reticulum stress, partially alleviates lipid-induced insulin resistance and-cell dysfunction in humans. Diabetes. 2011;60:918-924.
43. Erbay E , Babaev VR, Mayers JR, et al. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat Med. 2009;15:1383-1391.
44. Kim PS, Lee J, Jongsa mak P, et al. Defective protein folding and intracellular retention of thyroglobulin-R19K mutant as a cause of human congenital goiter. Mol Endocrinol. 2008;22:477-484.
45. Chiovato L, Martino E, Tonacchera M, et al. Studies on the in vitro cytotoxic effect of amiodarone. Endocrinology. 1994;134:2277-2282.
46. Di Matola T, D'Ascoli F, Fenzi G, et al. Amiodarone induces cytochrom e c release and apoptosis through an iodine-independent mechanism. J Clin Endocrinol Metab. 2000;85:4323-4330.
47. Gupta SS, Ton VK, Beaudry V, Rulli S, Cunningham K, Rao R. Antifungal ac tivity of amiodarone is mediated by disruption of calcium homeostasis. J Biol Chem. 2003;278:28831-28839.
48. Iannone P, Haupt E, Flego G, et al. Dronedarone for atrial fibrillation: The limited reliability of clinical practice guidelines. JAMA Intern Med. 2014;174:625-629.
49. Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678-2687.
50. Cao SS, Kaufman RJ. Targeting endoplasmic reticulum stress in metabolic disease. Expert Opin Ther Targets. 2013;17:437-448.
51. Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood. 1995;85:43-49.
52. KaplanM M,GershwinME.Primary biliary cirrhosis.NEngl JMed. 2005 353 1261-1273.